Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb., PMID:9600913
Vitaxin, a humanized monoclonal antibody to the vitronectin receptor (alphavbeta3), reduces neointimal hyperplasia and total vessel area after balloon injury in hypercholesterolemic rabbits., PMID:10364564
[Recent progress in clinical trials with antimetastatic drugs]., PMID:10553408
Monoclonal antibodies to alphaVbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor., PMID:10627437
Increased flow precedes remote arteriolar dilations for some microapplied agonists., PMID:10749713
Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3., PMID:10955784
Snake venom protein paralyzes cancer cells., PMID:11181769
Vitaxin applied molecular evolution., PMID:11249574
A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer., PMID:11385959
Pilot study of vitaxin--an angiogenesis inhibitor-in patients with advanced leiomyosarcomas., PMID:11571751
The role of alpha(v)beta3 integrins in vascular healing., PMID:11858476
MedImmune initiates phase I/II clinical study with Vitaxin., PMID:12113018
A reevaluation of integrins as regulators of angiogenesis., PMID:12205444
Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases., PMID:12379637
Modeling and analysis of protein design under resource constraints., PMID:15767779
Targeting angiogenesis with antibodies for the treatment of cancer., PMID:16118694
[Research on the antimetastatic agents]., PMID:16201504
Integrins: molecular targets in cancer therapy., PMID:16507218
Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism., PMID:17017851
In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3., PMID:17018625
Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin., PMID:17172415
Effects of Vitaxin, a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro., PMID:17390341
Asthma remission in a patient with rheumatoid arthritis while on antiangiogenesis therapy during a rheumatoid arthritis trial demonstrated by forced oscillation and spirometry., PMID:17530526
Gateways to clinical trials., PMID:17805439
Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors., PMID:17876527
Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer., PMID:18953435
Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme., PMID:19010848
Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer., PMID:19829059
A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma., PMID:20108344
Specific targeting of human integrin α(v)β (3) with (111)In-labeled Abegrin™ in nude mouse models., PMID:20383594
Pharmacodynamic (phase 0) study using etaracizumab in advanced melanoma., PMID:20445352
Gateways to clinical trials., PMID:21069103
Metastatic melanoma - a review of current and future drugs., PMID:24432031
The Therapeutic Antibody LM609 Selectively Inhibits Ligand Binding to Human αVβ3 Integrin via Steric Hindrance., PMID:29033288
MedImmune initiates phase I/II clinical study with Vitaxin, PMID: 12113018
Vitaxin, a humanized monoclonal antibody to the vitronectin receptor (alphavbeta3), reduces neointimal hyperplasia and total vessel area after balloon injury in hypercholesterolemic rabbits, PMID: 10364564
A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer, PMID: 11385959
Asthma remission in a patient with rheumatoid arthritis while on antiangiogenesis therapy during a rheumatoid arthritis trial demonstrated by forced oscillation and spirometry, PMID: 17530526
Monoclonal antibodies to alphaVbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor, PMID: 10627437
Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb, PMID: 9600913
Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3, PMID: 10955784
Increased flow precedes remote arteriolar dilations for some microapplied agonists, PMID: 10749713
Modeling and analysis of protein design under resource constraints, PMID: 15767779
In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3, PMID: 17018625
Pilot study of vitaxin--an angiogenesis inhibitor-in patients with advanced leiomyosarcomas, PMID: 11571751
Effects of Vitaxin, a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro, PMID: 17390341
Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin, PMID: 17172415
Specific targeting of human integrin α(v)β (3) with (111)In-labeled Abegrin™ in nude mouse models, PMID: 20383594
Targeting angiogenesis with antibodies for the treatment of cancer, PMID: 16118694
Snake venom protein paralyzes cancer cells, PMID: 11181769
The Therapeutic Antibody LM609 Selectively Inhibits Ligand Binding to Human α V β 3 Integrin via Steric Hindrance, PMID: 29033288
The role of alpha(v)beta3 integrins in vascular healing, PMID: 11858476
Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme, PMID: 19010848
[Research on the antimetastatic agents], PMID: 16201504
Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases, PMID: 12379637
[Recent progress in clinical trials with antimetastatic drugs], PMID: 10553408
Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism, PMID: 17017851
Metastatic melanoma - a review of current and future drugs, PMID: 24432031
A reevaluation of integrins as regulators of angiogenesis, PMID: 12205444
Integrins: molecular targets in cancer therapy, PMID: 16507218
Vitaxin applied molecular evolution, PMID: 11249574
Gateways to clinical trials, PMID: 21069103
Gateways to clinical trials, PMID: 17805439
Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer, PMID: 19829059
Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer, PMID: 18953435
Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors, PMID: 17876527
A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma, PMID: 20108344
Pharmacodynamic (phase 0) study using etaracizumab in advanced melanoma, PMID: 20445352
For research use only. Not for human or drug use.
